Literature DB >> 2418176

The kallikrein-kinin system as mediator in vasogenic brain edema. Part 3: Inhibition of the kallikrein-kinin system in traumatic brain swelling.

A Unterberg, C Dautermann, A Baethmann, W Müller-Esterl.   

Abstract

Evidence has previously been provided that administration of kinins to the cerebrum causes edema and opening of the blood-brain barrier. It has further been shown that these highly active compounds are formed in the brain under pathophysiological conditions. Their formation was enhanced when cerebral blood flow became compromised by an increase in intracranial pressure. Final evidence, however, was not available as to whether specific inhibition of the kallikrein-kinin (KK) system has a therapeutic function in acute head injury. The authors have demonstrated in rabbits that inhibition of the activating enzyme kallikrein by aprotinin or by aprotinin plus soybean trypsin inhibitor (SBTI), which interfere with plasma and tissue kallikrein, is associated with a decrease in formation of posttraumatic swelling after a standardized cold lesion to the brain. Saline-treated control animals with cerebral cold-induced injury had an increase in hemispheric weight 24 hours later of 13.0% +/- 0.8% (standard error of the mean) in the damaged hemisphere compared to the contralateral nondamaged hemisphere. Administration of aprotinin or aprotinin plus SBTI led to a significant reduction of hemispheric swelling of 10.1% +/- 0.7% or 10.4% +/- 0.7%, respectively. In animals receiving SBTI only, hemispheric swelling evolving from cold injury was not significantly reduced. Therapeutic reduction of brain edema by aprotinin cannot be attributed to a nonspecific effect on the blood pressure, which in the experimental groups remained almost normal as compared to the control animals. Failure of SBTI to influence posttraumatic brain swelling may have resulted from disturbances in intravascular coagulation. Measurements of aprotinin in plasma and tissue demonstrate that the inhibitor doses employed are within an effective therapeutic range. Attenuation of brain edema by specific inhibition of the KK system provides evidence for a mediator role of kinins in vasogenic edema. Clinical trials with inhibitors of the KK system in acute forms of traumatic lesions associated with vasogenic edema appear worthwhile.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418176     DOI: 10.3171/jns.1986.64.2.0269

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  14 in total

Review 1.  Critical appraisal of neuroprotection trials in head injury: what have we learned?

Authors:  Christos M Tolias; M Ross Bullock
Journal:  NeuroRx       Date:  2004-01

2.  The role of bradykinin in the etiology of vasogenic brain edema and perilesional brain dysfunction.

Authors:  I R Whittle; I R Piper; J D Miller
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

3.  Blood-brain barrier permeability and vascular reactivity to bradykinin after pretreatment with dexamethasone.

Authors:  L Schürer; P Temesvari; M Wahl; A Unterberg; A Baethmann
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 4.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

5.  Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation.

Authors:  Furat Raslan; Tobias Schwarz; Sven G Meuth; Madeleine Austinat; Michael Bader; Thomas Renné; Klaus Roosen; Guido Stoll; Anna-Leena Sirén; Christoph Kleinschnitz
Journal:  J Cereb Blood Flow Metab       Date:  2010-03-03       Impact factor: 6.200

6.  The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice.

Authors:  Raimund Trabold; Christian Erös; Klaus Zweckberger; Jane Relton; Heike Beck; Juerg Nussberger; Werner Müller-Esterl; Michael Bader; Eric Whalley; Nikolaus Plesnila
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-23       Impact factor: 6.200

7.  Development of hyperthermia following intracerebroventricular administration of endotoxin in the rat: effect of kinin B1 and B2 receptor antagonists.

Authors:  K Walker; A Dray; M Perkins
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

8.  LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia.

Authors:  Li Ding-Zhou; Isabelle Margaill; Bruno Palmier; Didier Pruneau; Michel Plotkine; Catherine Marchand-Verrecchia
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

9.  Activation of the coagulation system in the subarachnoid space after subarachnoid haemorrhage: serial measurement of fibrinopeptide A and bradykinin of cerebrospinal fluid and plasma in patients with subarachnoid haemorrhage.

Authors:  H Kasuya; T Shimizu; T Okada; K Takahashi; T Summerville; K Kitamura
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

Review 10.  Controversy in allergy. Neurologic allergy.

Authors:  L E Mansfield
Journal:  Clin Rev Allergy       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.